Literature DB >> 23098154

Cardiospheres and cardiosphere-derived cells as therapeutic agents following myocardial infarction.

Michelle Kreke1, Rachel Ruckdeschel Smith, Linda Marbán, Eduardo Marbán.   

Abstract

Heart disease is a major cause of morbidity and mortality. Cellular therapies hold significant promise for patients with heart disease. Heart-derived progenitor cells are capable of repairing a diseased heart through modulation of growth factor milieu and temporary engraftment leading to endogenous repair. The proof-of-concept CADUCEUS clinical trial using cardiosphere-derived cells has shown evidence of therapeutic cardiac tissue regeneration. Future clinical trials are now being planned to generate additional safety and efficacy data in the hopes of building toward an approved cellular therapy for heart disease.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23098154     DOI： 10.1586/erc.12.102

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN： 1477-9072


  22 in total

Review 1.  Use of stem cells in heart failure treatment: where we stand and where we are going.

Authors:  Luis A Sánchez; Carlos Enrique Guerrero-Beltrán; Andrea M Cordero-Reyes; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Oct-Dec

2.  Cadaveric cardiosphere-derived cells can maintain regenerative capacity and improve the heart function of cardiomyopathy.

Authors:  Yong Sun; Di Chi; Miaoxin Tan; Kai Kang; Maomao Zhang; Xiangyuan Jin; Xiaoping Leng; Rui Cao; Xianglan Liu; Bo Yu; Jian Wu
Journal:  Cell Cycle       Date:  2016-04-08       Impact factor: 4.534

3.  GMP-Grade Methods for Cardiac Progenitor Cells: Cell Bank Production and Quality Control.

Authors:  Gabriella Andriolo; Elena Provasi; Andrea Brambilla; Viviana Lo Cicero; Sabrina Soncin; Lucio Barile; Lucia Turchetto; Marina Radrizzani
Journal:  Methods Mol Biol       Date:  2021

4.  A Cell-Free SDKP-Conjugated Self-Assembling Peptide Hydrogel Sufficient for Improvement of Myocardial Infarction.

Authors:  Saman Firoozi; Sara Pahlavan; Mohammad-Hossein Ghanian; Shahram Rabbani; Shima Tavakol; Maryam Barekat; Saeed Yakhkeshi; Elena Mahmoudi; Mansoureh Soleymani; Hossein Baharvand
Journal:  Biomolecules       Date:  2020-01-30

5.  microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential.

Authors:  Li Qiao; Shiqi Hu; Suyun Liu; Hui Zhang; Hong Ma; Ke Huang; Zhenhua Li; Teng Su; Adam Vandergriff; Junnan Tang; Tyler Allen; Phuong-Uyen Dinh; Jhon Cores; Qi Yin; Yongjun Li; Ke Cheng
Journal:  J Clin Invest       Date:  2019-04-29       Impact factor: 14.808

Review 6.  Pathologic function and therapeutic potential of exosomes in cardiovascular disease.

Authors:  Shaina Ailawadi; Xiaohong Wang; Haitao Gu; Guo-Chang Fan
Journal:  Biochim Biophys Acta       Date:  2014-10-16

Review 7.  Cardiac stem cells: biology and clinical applications.

Authors:  Polina Goichberg; Jerway Chang; Ronglih Liao; Annarosa Leri
Journal:  Antioxid Redox Signal       Date:  2014-04-10       Impact factor: 8.401

8.  Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction).

Authors:  Konstantinos Malliaras; Raj R Makkar; Rachel R Smith; Ke Cheng; Edwin Wu; Robert O Bonow; Linda Marbán; Adam Mendizabal; Eugenio Cingolani; Peter V Johnston; Gary Gerstenblith; Karl H Schuleri; Albert C Lardo; Eduardo Marbán
Journal:  J Am Coll Cardiol       Date:  2013-09-11       Impact factor: 24.094

Review 9.  Is Cardioprotection Dead?

Authors:  David J Lefer; Eduardo Marbán
Journal:  Circulation       Date:  2017-07-04       Impact factor: 29.690

10.  Angiotensin II-Induced End-Organ Damage in Mice Is Attenuated by Human Exosomes and by an Exosomal Y RNA Fragment.

Authors:  Linda Cambier; Jorge F Giani; Weixin Liu; Takeshi Ijichi; Antonio K Echavez; Jackelyn Valle; Eduardo Marbán
Journal:  Hypertension       Date:  2018-06-04       Impact factor: 10.190
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.